Literature DB >> 8124662

Angiotensin II elevates cytosolic free calcium in human lung adenocarcinoma cells via activation of AT1 receptors.

V K Batra1, V Gopalakrishnan, J R McNeill, R A Hickie.   

Abstract

Angiotensin II (Ang II), bradykinin (BK), and endothelin-1 (ET-1) evoked alterations in cytosolic free calcium, [Ca2+]i, levels were determined using fura-2 fluorescence methodology in a human lung adenocarcinoma cell line (A549), a non-neoplastic lung cell line and a small cell lung carcinoma cell (SCLC) line. Ang II and BK evoked a rapid, concentration-dependent transient increase in [Ca2+]i in A549 cells. The peak [Ca2+]i increases attained with Ang II (1 microM) and BK (1 microM) were 3- and 4-fold higher, respectively (P < 0.01) than the basal [Ca2+]i values. This effect of Ang II was completely abolished by inclusion of losartan (DuP 753), an AT1 subtype selective antagonist. Removal of extracellular Ca2+ from the incubation medium led to significant diminution of the peak [Ca2+]i response to Ang II but not to BK. In contrast to Ang II and BK, ET-1 failed to evoke an increase in [Ca2+]i levels in A549 cells. Neither Ang II nor ET-1 evoked any appreciable increase in [Ca2+]i levels of non-neoplastic lung cell and SCLC cell lines. These data confirm that the human non-small cell lung cancer cells (A549) selectively express AT1 subtype receptors for Ang II that are functionally coupled to Ca2+ mobilization from both extra and intracellular sources.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8124662     DOI: 10.1016/0304-3835(94)90129-5

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  7 in total

1.  Angiotensin receptor blockers (ARBs) reduce the risk of lung cancer: a systematic review and meta-analysis.

Authors:  Jian Zhang; Jing Liu; Jianning Chen; Xiaojun Li; Yonghui Wu; Huiguo Chen; Weibin Wu; Kai Zhang; Lijia Gu
Journal:  Int J Clin Exp Med       Date:  2015-08-15

2.  Association between AT1 and AT2 angiotensin II receptor expression with cell proliferation and angiogenesis in operable breast cancer.

Authors:  Oscar Arrieta; Cynthia Villarreal-Garza; Gloria Vizcaíno; Benjamín Pineda; Norma Hernández-Pedro; Patricia Guevara-Salazar; Talia Wegman-Ostrosky; Geraldine Villanueva-Rodríguez; Armando Gamboa-Domínguez
Journal:  Tumour Biol       Date:  2015-02-15

Review 3.  Angiotensin peptides and lung cancer.

Authors:  Patricia E Gallagher; Katherine Cook; David Soto-Pantoja; Jyotsana Menon; E Ann Tallant
Journal:  Curr Cancer Drug Targets       Date:  2011-05       Impact factor: 3.428

4.  Cancer, inflammation and the AT1 and AT2 receptors.

Authors:  Gary Robert Smith; Sotiris Missailidis
Journal:  J Inflamm (Lond)       Date:  2004-09-30       Impact factor: 4.981

5.  Lack of an association between angiotensin receptor blocker based therapy and increased risk of cancer: evidence from large observational studies.

Authors:  Yuan Yang; Fan Zhang; Laura Skrip; Han Lei; Suxin Luo; Kai Lu; Dayi Hu
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

6.  Renin-Angiotensin system blockers may prolong survival of metastatic non-small cell lung cancer patients receiving erlotinib.

Authors:  Adnan Aydiner; Rumeysa Ciftci; Fatma Sen
Journal:  Medicine (Baltimore)       Date:  2015-06       Impact factor: 1.889

7.  Angiotensin II type 1 receptor (AT-1R) expression correlates with VEGF-A and VEGF-D expression in invasive ductal breast cancer.

Authors:  Aleksandra Jethon; Bartosz Pula; Aleksandra Piotrowska; Andrzej Wojnar; Janusz Rys; Piotr Dziegiel; Marzena Podhorska-Okolow
Journal:  Pathol Oncol Res       Date:  2012-05-12       Impact factor: 3.201

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.